Shc Proteins for Colon Cancer Prognosis
In August 2007, DiagnoCure acquired Catalyst Oncology and its lead proprietary prognostic tests for breast, colon and potentially other cancers. These will complement the Company’s GCC tests for colorectal cancer in helping physicians and patients in their treatment decisions.
The Shc protein-based tests have been validated in multiple clinical studies involving patients with five tumor types, including breast and colon. Results have shown the tests to be strong indicators for a patient’s risk of disease recurrence, as well as predictors of response to certain cancer therapies, such as tamoxifen or traditional chemotherapy. The tests measure the level of activated tyrosine phosphorylated (PY) Shc protein and p66 Shc protein in tissue specimens. The Shc proteins are involved in a number of well documented cellular pathways that are correlated with tumor aggressiveness across many types of cancer, offering a broad opportunity for clinical testing.